505 results on '"Valk, Peter J. M."'
Search Results
2. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
3. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
4. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia
5. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
6. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
7. Future Developments: Measurable Residual Disease
8. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
9. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia
10. PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse
11. Rearrangements involving 11q23.3/KMT2A in adult AML:mutational landscape and prognostic implications - a HARMONY study
12. Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.
13. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
14. Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia
15. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia
16. Future Developments: Measurable Residual Disease
17. The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia
18. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
19. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel
20. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
21. Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.
22. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
23. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
24. PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy
25. Prospective validation of the prognostic relevance of CD34$^{+}$CD38$^{-}$ AML stem cell frequency in the HOVON-SAKK132 trial
26. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
27. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
28. Rearrangements involving 11q23.3/KMT2Ain adult AML: mutational landscape and prognostic implications – a HARMONY study
29. A 17-gene stemness score for rapid determination of risk in acute leukaemia
30. A congenital CSF3R mutation in chronic neutropenia reveals a vital role for a cytokine receptor extracellular hinge motif in the response to granulocyte colony‐stimulating factor
31. Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloid Leukemia
32. The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed
33. A congenital CSF3R mutation in chronic neutropenia reveals a vital role for a cytokine receptor extracellular hinge motif in the response to granulocyte colony‐stimulating factor.
34. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
35. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
36. The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
37. Review: Aberrant EVI1 expression in acute myeloid leukaemia
38. A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
39. Azacytidine Treatment for VEXAS Syndrome
40. DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
41. Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
42. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
43. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
44. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
45. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.
46. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
47. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial
48. Disruption of CSF-1R signaling inhibits growth of AML with inv(16)
49. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
50. The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.